Rheumatoid arthritis (RF), referred to as “rheumatoid arthritis”, is a systemic autoimmune disease with erosive arthritis as the main manifestation. Rheumatoid arthritis can occur at any age, with a peak incidence between the ages of 30 and 50. The main manifestation of rheumatoid arthritis is a symmetric, persistent polyarthritis involving mainly the small joints of the hands and wrists. The pathology is characterized by chronic inflammation of the synovial membrane, formation of vascular opacities, and destruction of articular cartilage and bone, which can eventually lead to joint deformity and loss of function. In addition, patients may also have systemic manifestations such as fever and fatigue. In 2009, the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) proposed a new classification and scoring system for rheumatoid arthritis that can help diagnose atypical and early rheumatoid arthritis. In clinical work, due to the vigilance of the disease, there are not many “missed diagnoses” of the disease, but instead it is easy to misdiagnose osteoarthritis, osteoporosis, traumatic arthritis, tenosynovitis, and even gout as rheumatoid arthritis. On the other hand, for some clearly diagnosed rheumatoid arthritis, only non-steroidal anti-inflammatory drugs plus glucocorticoids (prednisone) are used, so that many patients lose valuable early treatment opportunities. At present, the international treatment principle for rheumatoid arthritis has been more unified, advocating the use of NSAIDs along with methotrexate, hydroxychloroquine, salazosulfapyridine, leflunomide and other “disease-modifying anti-rheumatic drugs” (DMARDs), while selective combination of some plant drugs can really improve the disease and control the The effect of the disease development. In the last decade, the use of biologic agents targeting cytokines has given patients a new outlook in terms of further control of disease progression, remission or minimal disease activity. It is important for patients with wind-like disease to have a proper understanding of this common disease, build confidence in overcoming the disease, and actively cooperate with their doctors in treatment. The majority of patients with wind-like disease can achieve clinical remission with systematic and standardized medical treatment.